title: Clinical presentation and outcome of squamous cell carcinoma of the anus in HIV-infected patients in the HAART-era: a GICAT experience.
abstract: BACKGROUND
  Squamous cell carcinoma of the anus (SCCA) is a relatively uncommon cancer. In the HIV-positive patients the introduction of the highly active antiretroviral therapy (HAART) did not change the incidence of SCCA.
  
  
  OBJECTIVE
  This paper describes the Italian Cooperative Group on AIDS and Tumours (GICAT) experience on HIV-positive patients with SCCA. The purposes of this retrospective study were: first to describe the clinical presentation and outcome of HIV-positive patients with SCCA, second to compare them with the ones reported in the literature.
  
  
  METHODS
  Between July 2000 and March 2010 we retrospectively collected epidemiological, clinical and survival data from 65 patients with SCCA in HIV infection enrolled within the GICAT.
  
  
  RESULTS
  Fifty-three (81.5%) patients were male. The majority of patients (40%) were homosexual Forty-three patients (66.1%) were diagnosed with HIV before 1996. Thirty-five patients (54%) had CD4-positive cells count > 200 / mm3 and 28 patients (43%) had viral load > 50 cp / ml at the time of SCCA diagnosis. The median time difference between HIV and SCCA diagnosis was 120 months (range 10-282 months). Sixty-one patients (96.8%) received HAART at SCCA diagnosis. Fifty-two patients (80%) had performance status (PS) 0-1 at the time of SCCA diagnosis. Twenty-seven patients (41.5%) underwent surgery with curative intent. Thirty-five patients (53.9%) were given combined modality therapy (CMT) consisting of pelvic radiotherapy with concurrent chemotherapy. No grade 3/4 haematological or extra-haematological effects were observed in our patients.
  
  
  CONCLUSIONS
  In summary, despite the retrospective nature of analysis, the absence of patient strict criteria of inclusion/exclusion, our data on HIV-positive patients with SCCA, compared both to general population and to small reports on HIV-positive patients present in the literature, are promising.
authors.affiliation: Division of Medical Oncology A, National Cancer Institute, Aviano, Pordenone, Italy. fmartellotta@cro.it
authors.forename: F
authors.initials: F
authors.lastname: Martellotta
authors.forename: M
authors.initials: M
authors.lastname: Berretta
authors.forename: B
authors.initials: B
authors.lastname: Cacopardo
authors.forename: R
authors.initials: R
authors.lastname: Fisichella
authors.forename: O
authors.initials: O
authors.lastname: Schioppa
authors.forename: A
authors.initials: A
authors.lastname: Zanghì
authors.forename: D
authors.initials: D
authors.lastname: Spartà
authors.forename: A
authors.initials: A
authors.lastname: Cappellani
authors.forename: R
authors.initials: R
authors.lastname: Talamini
authors.forename: I
authors.initials: I
authors.lastname: Izzi
authors.forename: A
authors.initials: A
authors.lastname: Ridolfo
authors.forename: A
authors.initials: A
authors.lastname: Torresin
authors.forename: F
authors.initials: F
authors.lastname: Fiorica
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D001005:Anus Neoplasms / Q000401:mortality* / Q000628:therapy; D018791:CD4 Lymphocyte Count; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate